Free Trial
NYSE:NBY

NovaBay Pharmaceuticals 11/9/2023 Earnings Report

NovaBay Pharmaceuticals logo
$0.56 0.00 (-0.58%)
As of 05/28/2025 03:57 PM Eastern

NovaBay Pharmaceuticals EPS Results

Actual EPS
-$12.95
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

NovaBay Pharmaceuticals Revenue Results

Actual Revenue
$3.27 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

NovaBay Pharmaceuticals Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

NovaBay Pharmaceuticals Earnings Headlines

White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
NovaBay Pharmaceuticals approves liquidation plan
See More NovaBay Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NovaBay Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NovaBay Pharmaceuticals and other key companies, straight to your email.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals (NYSE:NBY), a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

View NovaBay Pharmaceuticals Profile

More Earnings Resources from MarketBeat